A photo of Jennifer Picarsic.

Jennifer L. Picarsic, MD


  • Co-Director, Histiocytosis Center
  • Staff Pathologist, Division of Pathology
  • Associate Professor, UC Department of Pathology and Laboratory Medicine
Every tissue slide I examine represents a patient. I care deeply about providing the most accurate and timely diagnosis based on the advanced tools available to me as a pathologist.

About

Biography

As a pediatric pathologist, I study cells on a slide to help make a diagnosis. I specialize in histiocytic neoplasms, a rare group of white blood cell disorders that affect both pediatric and adult patients. I review pathology consultations from around the world right here at Cincinnati Children’s Hospital Medical Center.

Every tissue slide I examine represents a patient. I care deeply about providing the most accurate and timely diagnosis based on the advanced tools available to me as a pathologist.

I enjoy seeing diseases in full color under the microscope, and now with digital pathology technology, also on the computer screen. Although I don't typically see patients in person, I do know them through their tissues and disease. I am honored to provide "behind the scenes" education to doctors about diseases so they can treat patients in the best manner.

As the co-director of the Histiocytosis Center at Cincinnati Children’s together with Dr. Ashish Kumar of the Cincinnati Children’s Cancer and Blood Diseases Institute, we are leading the field in the diagnosis and treatment of LCH and related histiocytic diseases.

My research focuses on the pathobiology of histiocytic neoplasms.

I was honored to be the 2018 recipient of the Histiocyte Society’s Nesbit Award in Clinical Science. The award honors collaborative research efforts on the molecular biology of juvenile xanthogranuloma lesions.

In my free time, I am an avid bike spinner, lover of travel, and hold another full-time job as a mother of two.

Publications

Selected

International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Goyal, G; Tazi, A; Go, RS; Rech, KL; Picarsic, JL; Vassallo, R; Young, JR; Cox, CW; Van Laar, J; Hermiston, ML; et al. Blood. 2022; 139:2601-2621.

Selected

ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Kemps, PG; Picarsic, J; Durham, BH; Hélias-Rodzewicz, Z; Hiemcke-Jiwa, L; van den Bos, C; van de Wetering, MD; van Noesel, CJ M; van Laar, JA M; Verdijk, RM; et al. Blood. 2022; 139:256-280.

Selected

Histiocytic disorders. McClain, KL; Bigenwald, C; Collin, M; Haroche, J; Marsh, RA; Merad, M; Picarsic, J; Ribeiro, KB; Allen, CE. Nature Reviews Disease Primers. 2021; 7.

Selected

BRAF fusions in pediatric histiocytic neoplasms define distinct therapeutic responsiveness to RAF paradox breakers. Jain, P; Surrey, LF; Straka, J; Russo, P; Womer, R; Li, MM; Storm, PB; Waanders, AJ; Hogarty, MD; Resnick, AC; et al. Pediatric Blood and Cancer. 2021; 68.

Selected

Discrepancies between F-18-FDG PET/CT findings and conventional imaging in Langerhans cell histiocytosis. Ferrell, J; Sharp, S; Kumar, A; Jordan, M; Picarsic, J; Nelson, A. Pediatric Blood and Cancer. 2021; 68.

Selected

Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era. Goyal, G; Heaney, ML; Collin, M; Cohen-Aubart, F; Vaglio, A; Durham, BH; Hershkovitz-Rokah, O; Girschikofsky, M; Jacobsen, ED; Toyama, K; et al. Blood. 2020; 135:1929-1945.

Selected

BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease. Picarsic, J; Pysher, T; Zhou, H; Fluchel, M; Pettit, T; Whitehead, M; Surrey, LF; Harding, B; Goldstein, G; Fellig, Y; et al. Acta neuropathologica communications. 2019; 7.

Selected

Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Durham, BH; Rodrigo, EL; Picarsic, J; Abramson, D; Rotemberg, V; De Munck, S; Pannecoucke, E; Lu, SX; Pastore, A; Yoshimi, A; et al. Nature Medicine. 2019; 25:1839-1842.

Selected

Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis. Albeituni, S; Verbist, KC; Tedrick, PE; Tillman, H; Picarsic, J; Bassett, R; Nichols, KE. Blood. 2019; 134:147-159.

Selected

BRAF-V600E-mutated Rosai-Dorfman-Destombes disease and Langerhans cell histiocytosis with response to BRAF inhibitor. Mastropolo, R; Close, A; Allen, SW; McClain, KL; Maurer, S; Picarsic, J. Blood Advances. 2019; 3:1848-1853.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey